Your browser doesn't support javascript.
loading
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera, Mercedes; Reig, Òscar; Milà-Guasch, Maria; Font, Albert; Domènech, Montserrat; Rodríguez-Vida, Alejo; Carles, Joan; Suárez, Cristina; Del Alba, Aránzazu González; Jiménez, Natalia; Victoria, Iván; Sala-González, Núria; Ribal, Maria José; López, Sandra; Etxaniz, Olatz; Anguera, Geòrgia; Maroto, Pablo; Fernández, Pedro Luis; Prat, Aleix; Mellado, Begoña.
Afiliación
  • Marín-Aguilera M; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Reig Ò; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.
  • Milà-Guasch M; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Font A; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Domènech M; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.
  • Rodríguez-Vida A; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Carles J; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Suárez C; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Del Alba AG; Department of Medical Oncology, Institut Català d'Oncologia, Badalona, Spain.
  • Jiménez N; Department of Medical Oncology, Fundació Althaia, Barcelona, Spain.
  • Victoria I; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Sala-González N; Department of Medical Oncology, Vall d'Hebron Institute of Oncology. Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ribal MJ; Department of Medical Oncology, Vall d'Hebron Institute of Oncology. Vall d'Hebron University Hospital, Barcelona, Spain.
  • López S; Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Etxaniz O; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Anguera G; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Maroto P; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Fernández PL; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.
  • Prat A; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Mellado B; Department of Medical Oncology, Institut Català d'Oncologia, Girona, Spain.
Int J Cancer ; 145(7): 1970-1981, 2019 10 01.
Article en En | MEDLINE | ID: mdl-30807643
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Feniltiohidantoína / Biomarcadores de Tumor / Proteínas de Fusión Oncogénica / Resistencia a Antineoplásicos / Neoplasias de la Próstata Resistentes a la Castración / Docetaxel Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Int J Cancer Año: 2019 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Feniltiohidantoína / Biomarcadores de Tumor / Proteínas de Fusión Oncogénica / Resistencia a Antineoplásicos / Neoplasias de la Próstata Resistentes a la Castración / Docetaxel Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Int J Cancer Año: 2019 Tipo del documento: Article País de afiliación: España